Wells Fargo Sticks to Its Buy Rating for United Therapeutics (UTHR)
TD Cowen Adjusts Price Target on United Therapeutics to $350 From $270, Maintains Buy Rating
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
Morgan Stanley Maintains Overweight on United Therapeutics, Lowers Price Target to $314
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
United Therapeutics (UTHR) Receives a Buy From Wedbush
Ladenburg Thalmann Maintains Buy on United Therapeutics, Raises Price Target to $268
Wedbush Lifts United Therapeutics' Price Target to $307 From $305 After 'Strong' Q2 Results, Keeps Outperform Rating
United Therapeutics Analyst Ratings
The Latest Analyst Ratings for United Therapeutics